Emil J Freireich Leukemia Hematology Grand Rounds

1. Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes.
2. Interpret the available data for treatment of intermediate or high-risk Myelofibrosis.
3. Incorporate new options for Myelodysplastic Syndrome in practice.
4. Utilize and implement new strategies for treating Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia and other hematological cancers in clinical practice.

In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

View the accessibility policy for The University of Texas M.D Anderson Cancer Center.

The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Abhishek Maiti, MD
Assistant Professor
UT MDACC

Activity Co-Director

Farhad Ravandi-Kashani, MD
Professor
MD Anderson Cancer Center

Activity Director

Grant or research support-Other-Amgen|Grant or research support-Other-Xencor|Grant or research support-Other-Taiho|Grant or research support-Other-Abbvie|Grant or research support-Other-Astex|Grant or research support-Other-Huctichon|Grant or research support-Other-Prelude|Paid consultant-Other-Celgene|Paid consultant-Other-Bristol Myers Squibb|Paid consultant-Other-AstraZeneca|Paid consultant-Other-Novartis|Paid consultant-Other-Agios|Paid consultant-Other-Pfizer|Paid consultant-Other-Jazz

Hagop M. Kantarjian, MD
Chair, Leukemia
The University of Texas MD Anderson Cancer Center

Other Planning Committee Member

Grant or research support-Other-AbbVie|Grant or research support-Other-Amgen|Grant or research support-Other-Ascentage|Grant or research support-Bristol-Myers Squibb|Grant or research support-Daiichi Sankyo|Grant or research support-Other-Immunogen|Grant or research support-Other-Jazz|Grant or research support-Pfizer, Inc.|Grant or research support-Sanofi-Aventis|Honoraria-Other-AbbVie|Honoraria-Other-Actinium|Honoraria-Other-Adaptive Biotechnologies|Honoraria-Other-Amgen|Honoraria-Other-Apptitude Health|Honoraria-Other-BioAscend|Honoraria-Daiichi Sankyo|Honoraria-Other-Delta Fly|Honoraria-Other-Janssen Global|Honoraria-Novartis AG|Honoraria-Other-Oxford Biometical|Honoraria-Pfizer, Inc.|Honoraria-Takeda Pharmaceuticals, Inc.

We wish to acknowledge AstraZeneca and Servier Pharmaceuticals for their support of this activity.